CN103717597B - 作为激酶抑制剂的杂环化合物 - Google Patents
作为激酶抑制剂的杂环化合物 Download PDFInfo
- Publication number
- CN103717597B CN103717597B CN201280019590.1A CN201280019590A CN103717597B CN 103717597 B CN103717597 B CN 103717597B CN 201280019590 A CN201280019590 A CN 201280019590A CN 103717597 B CN103717597 B CN 103717597B
- Authority
- CN
- China
- Prior art keywords
- pyrazolo
- quinolin
- methoxy
- amine
- amino
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- VIPMBJSGYWWHAO-UHFFFAOYSA-N CC(C)(C)c(cc1)ccc1C(N)=O Chemical compound CC(C)(C)c(cc1)ccc1C(N)=O VIPMBJSGYWWHAO-UHFFFAOYSA-N 0.000 description 1
- KDBRLTTUWOYSKY-UHFFFAOYSA-N CC(C=CC=C1B2OC(C)(C)C(C)(C)O2)C=C1N Chemical compound CC(C=CC=C1B2OC(C)(C)C(C)(C)O2)C=C1N KDBRLTTUWOYSKY-UHFFFAOYSA-N 0.000 description 1
- HACUBXAMQFMPQT-UHFFFAOYSA-N CCCc1cc(C)ccc1OCC(C)=O Chemical compound CCCc1cc(C)ccc1OCC(C)=O HACUBXAMQFMPQT-UHFFFAOYSA-N 0.000 description 1
- TVCAWPIWFDXTDV-UHFFFAOYSA-N COC(c1n[n](Cc(cc2)ccc2OC)cc1[Br]=C)=O Chemical compound COC(c1n[n](Cc(cc2)ccc2OC)cc1[Br]=C)=O TVCAWPIWFDXTDV-UHFFFAOYSA-N 0.000 description 1
- CATAGJZATFZGMJ-UHFFFAOYSA-N Cc(cc1)cnc1N1CCN(C)CC1 Chemical compound Cc(cc1)cnc1N1CCN(C)CC1 CATAGJZATFZGMJ-UHFFFAOYSA-N 0.000 description 1
- JJYPMNFTHPTTDI-UHFFFAOYSA-N Cc1cc(N)ccc1 Chemical compound Cc1cc(N)ccc1 JJYPMNFTHPTTDI-UHFFFAOYSA-N 0.000 description 1
- HMMPHXCOTBASBC-UHFFFAOYSA-N Cc1cc([nH]nc2)c2cc1 Chemical compound Cc1cc([nH]nc2)c2cc1 HMMPHXCOTBASBC-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/08—Antiseborrheics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D495/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
- C07D513/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Dermatology (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Ophthalmology & Optometry (AREA)
- Urology & Nephrology (AREA)
- Physical Education & Sports Medicine (AREA)
- Otolaryngology (AREA)
- Transplantation (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161517581P | 2011-04-21 | 2011-04-21 | |
| US61/517,581 | 2011-04-21 | ||
| PCT/EP2012/001736 WO2012143143A1 (en) | 2011-04-21 | 2012-04-23 | Heterocyclic compounds as kinase inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103717597A CN103717597A (zh) | 2014-04-09 |
| CN103717597B true CN103717597B (zh) | 2017-07-04 |
Family
ID=46001141
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201280019590.1A Active CN103717597B (zh) | 2011-04-21 | 2012-04-23 | 作为激酶抑制剂的杂环化合物 |
Country Status (25)
| Country | Link |
|---|---|
| US (1) | US9499535B2 (enExample) |
| EP (1) | EP2699572B1 (enExample) |
| JP (1) | JP6278406B2 (enExample) |
| KR (1) | KR101649610B1 (enExample) |
| CN (1) | CN103717597B (enExample) |
| AP (1) | AP2013007252A0 (enExample) |
| AU (1) | AU2012244549B2 (enExample) |
| BR (1) | BR112013026744B1 (enExample) |
| CA (1) | CA2831680C (enExample) |
| CL (1) | CL2013003052A1 (enExample) |
| CO (1) | CO6831983A2 (enExample) |
| CR (1) | CR20130537A (enExample) |
| CU (1) | CU20130144A7 (enExample) |
| EA (1) | EA034193B1 (enExample) |
| EC (1) | ECSP13012984A (enExample) |
| GT (1) | GT201300259A (enExample) |
| IL (1) | IL228967B (enExample) |
| MA (1) | MA35123B1 (enExample) |
| MX (1) | MX365784B (enExample) |
| PE (1) | PE20140927A1 (enExample) |
| PH (1) | PH12013502184A1 (enExample) |
| SG (1) | SG194216A1 (enExample) |
| TN (1) | TN2013000422A1 (enExample) |
| TW (1) | TWI557121B (enExample) |
| WO (1) | WO2012143143A1 (enExample) |
Families Citing this family (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5918848B2 (ja) | 2011-04-21 | 2016-05-18 | ギリアード サイエンシーズ， インコーポレイテッド | ベンゾチアゾール化合物およびその薬学的使用 |
| KR101649610B1 (ko) | 2011-04-21 | 2016-08-19 | 오리제니스 게엠베하 | 키나아제 억제제로서의 헤테로사이클릭 화합물 |
| US9284323B2 (en) | 2012-01-04 | 2016-03-15 | Gilead Sciences, Inc. | Naphthalene acetic acid derivatives against HIV infection |
| US9376392B2 (en) | 2012-01-04 | 2016-06-28 | Gilead Sciences, Inc. | 2-(tert-butoxy)-2-(7-methylquinolin-6-yl) acetic acid derivatives for treating AIDS |
| AR090650A1 (es) | 2012-04-12 | 2014-11-26 | Alcon Res Ltd | Tratamiento para respuestas inflamatorias inducidas por microbios en el ojo |
| CA2878054C (en) | 2012-06-29 | 2018-09-11 | Pfizer Inc. | Novel 4-(substituted-amino)-7h-pyrrolo[2,3-d]pyrimidines as lrrk2 inhibitors |
| CN112587658A (zh) | 2012-07-18 | 2021-04-02 | 博笛生物科技有限公司 | 癌症的靶向免疫治疗 |
| US10000482B2 (en) * | 2012-10-19 | 2018-06-19 | Origenis Gmbh | Kinase inhibitors |
| PL2970333T3 (pl) * | 2013-03-15 | 2017-12-29 | Oncodesign S.A. | Makrocykliczne inhibitory kinazy LRRK2 |
| WO2015026683A1 (en) * | 2013-08-22 | 2015-02-26 | Merck Sharp & Dohme Corp. | Compounds inhibiting leucine-rich repeat kinase enzyme activity |
| WO2015082887A2 (en) * | 2013-12-02 | 2015-06-11 | Bergenbio As | Use of kinase inhibitors |
| JP6487921B2 (ja) | 2013-12-17 | 2019-03-20 | ファイザー・インク | ＬＲＲＫ２阻害薬としての新規の３，４−二置換−１Ｈ−ピロロ［２，３−ｂ］ピリジンおよび４，５−二置換−７Ｈ−ピロロ［２，３−ｃ］ピリダジン |
| SG11201605449YA (en) | 2014-01-10 | 2016-08-30 | Birdie Biopharmaceuticals Inc | Compounds and compositions for immunotherapy |
| EP4001311B1 (en) | 2014-07-09 | 2025-11-05 | Birdie Biopharmaceuticals Inc. | Anti-pd-l1/pd-1 combinations for treating tumors |
| WO2016007540A2 (en) | 2014-07-10 | 2016-01-14 | The J. David Gladstone Institutes | Compositions and methods for treating dengue virus infection |
| CN112546238A (zh) | 2014-09-01 | 2021-03-26 | 博笛生物科技有限公司 | 用于治疗肿瘤的抗-pd-l1结合物 |
| EP3662751B1 (en) * | 2015-05-26 | 2021-10-13 | Kaohsiung Medical University | Pyrazolo[4,3-c]quinoline derivatives for inhibition of b-glucuronidase |
| WO2017046675A1 (en) * | 2015-09-14 | 2017-03-23 | Pfizer Inc. | Novel imidazo [4,5-c] quinoline and imidazo [4,5-c][1,5] naphthyridine derivatives as lrrk2 inhibitors |
| CN105664178B (zh) * | 2015-09-24 | 2019-08-20 | 洪健 | Syk作为肝纤维化/硬化治疗靶点的应用 |
| CN115350279A (zh) | 2016-01-07 | 2022-11-18 | 博笛生物科技有限公司 | 用于治疗肿瘤的抗-her2组合 |
| CN106943597A (zh) | 2016-01-07 | 2017-07-14 | 博笛生物科技（北京）有限公司 | 用于治疗肿瘤的抗-egfr组合 |
| CN106943596A (zh) | 2016-01-07 | 2017-07-14 | 博笛生物科技（北京）有限公司 | 用于治疗肿瘤的抗-cd20组合 |
| US10034861B2 (en) | 2016-07-04 | 2018-07-31 | H. Lundbeck A/S | 1H-pyrazolo[4,3-b]pyridines as PDE1 inhibitors |
| AU2017384388B2 (en) | 2016-12-20 | 2020-09-17 | Astrazeneca Ab | Amino-triazolopyridine compounds and their use in treating cancer |
| AU2018236286B2 (en) * | 2017-03-16 | 2022-02-17 | Bristol-Myers Squibb Company | Forms and compositions of a MK2 inhibitor |
| CN118515666A (zh) * | 2017-04-27 | 2024-08-20 | 博笛生物科技有限公司 | 2-氨基-喹啉衍生物 |
| US11517567B2 (en) | 2017-06-23 | 2022-12-06 | Birdie Biopharmaceuticals, Inc. | Pharmaceutical compositions |
| HUE057202T2 (hu) | 2017-12-14 | 2022-04-28 | H Lundbeck As | Kombinációs kezelések 1H-pirazolo[4,3-b]piridinek alkalmazásával |
| AR113926A1 (es) | 2017-12-14 | 2020-07-01 | H Lundbeck As | Derivados de 1h-pirazolo[4,3-b]piridinas |
| WO2019121840A1 (en) | 2017-12-20 | 2019-06-27 | H. Lundbeck A/S | Pyrazolo[3,4-b]pyridines and imidazo[1,5-b]pyridazines as pde1 inhibitors |
| NZ769136A (en) * | 2018-04-25 | 2024-04-26 | Innate Tumor Immunity Inc | Nlrp3 modulators |
| JP2020132986A (ja) * | 2019-02-25 | 2020-08-31 | 東京エレクトロン株式会社 | 成膜用組成物および成膜方法 |
| CN116854706B (zh) * | 2019-04-18 | 2025-11-04 | 四川科伦博泰生物医药股份有限公司 | 稠环化合物、其制备方法及用途 |
| AU2020345000A1 (en) | 2019-09-13 | 2022-03-31 | Origenis Gmbh | 1,4-dihydrobenzo[d]pyrazolo[3,4-f][1,3]diazepine derivatives and related compounds as LRRK2, NUAK1 and/or TYK2 kinase modulators for the treatment of e.g. autoimmune disease |
| KR20220062038A (ko) * | 2019-09-13 | 2022-05-13 | 오리제니스 게엠베하 | 예를 들어 자가면역 질환의 치료를 위한 lrrk2, nuak1 및/또는 tyk2 키나제 조정제로서의 1,4-디히드로벤조[d]피라졸로[3,4-f][1,3]디아제핀 유도체 및 관련 화합물 |
| AU2020386436A1 (en) * | 2019-11-20 | 2022-05-26 | Yale University | Compounds, compositions, and methods for treating ischemia-reperfusion injury and/or lung injury |
| WO2021207141A1 (en) * | 2020-04-06 | 2021-10-14 | The Regents Of The University Of Colorado, A Body Corporate | METHODS OF USING NEUROKININ-1 RECEPTOR (NK-1R) ANTAGONISTS TO TREAT β-CORONAVIRUS INFECTION INCLUDING SARS-COV-2 INFECTION AND/OR COVID-19 DISEASE |
| WO2022007713A1 (zh) * | 2020-07-06 | 2022-01-13 | 军事科学院军事医学研究院军事兽医研究所 | 牛磺罗定在抗病毒中的应用 |
| WO2022079250A1 (en) * | 2020-10-16 | 2022-04-21 | Merck Patent Gmbh | Compounds for the treatment of viral infections |
| CN112138015B (zh) * | 2020-10-22 | 2022-08-05 | 合肥博思科创医药科技有限公司 | 三苄糖苷在治疗微循环障碍引起的皮肤疾病中的应用 |
| WO2022093685A1 (en) * | 2020-10-26 | 2022-05-05 | Neuron23, Inc. | Methods of treatment and diagnosis of parkinson's disease associated with wild-type lrrk2 |
| CN120865213A (zh) * | 2021-02-03 | 2025-10-31 | 苏州欧康维视生物科技有限公司 | 吡唑取代的咪唑并[1,2-a]喹喔啉衍生物的盐型及晶型 |
| WO2023076404A1 (en) | 2021-10-27 | 2023-05-04 | Aria Pharmaceuticals, Inc. | Methods for treating systemic lupus erythematosus |
| CN114931573A (zh) * | 2022-01-13 | 2022-08-23 | 浙江中医药大学 | 依普黄酮在抑制nlrp3炎症小体活化中的应用 |
| US11981676B1 (en) | 2024-01-16 | 2024-05-14 | King Faisal University | Pyrazolo[4,3-c][2,6]naphthyridines as CK2 inhibitors |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CY1357A (en) | 1979-06-21 | 1987-08-07 | Ciba Geigy Ag | Pyrazolo-quinolines, processes for their production, pharmaceutical compositions containing them and their therapeutical use |
| US5360720A (en) | 1993-10-08 | 1994-11-01 | Alcon Laboratories, Inc. | Method of preparing human conjunctival mast cells for mast cell stabilization assays |
| US5723608A (en) | 1996-12-31 | 1998-03-03 | Neurogen Corporation | 3-aryl substituted pyrazolo 4,3-d!pyrimidine derivatives; corticotropin-releasing factor receptor (CRF1) specific ligands |
| US6531475B1 (en) | 1998-11-12 | 2003-03-11 | Neurocrine Biosciences, Inc. | CRF receptor antagonists and methods relating thereto |
| GB0106661D0 (en) | 2001-03-16 | 2001-05-09 | Pfizer Ltd | Pharmaceutically active compounds |
| EP1696912B1 (en) * | 2003-10-03 | 2016-05-11 | 3M Innovative Properties Company | Pyrazolopyridines and analogs thereof |
| US7544697B2 (en) * | 2003-10-03 | 2009-06-09 | Coley Pharmaceutical Group, Inc. | Pyrazolopyridines and analogs thereof |
| US7384930B2 (en) | 2004-11-03 | 2008-06-10 | Bristol-Myers Squibb Company | Constrained compounds as CGRP-receptor antagonists |
| JP2008538119A (ja) * | 2005-04-01 | 2008-10-09 | コーリー ファーマシューティカル グループ，インコーポレーテッド | ピラゾロ［３，４−ｃ］キノリン類、ピラゾロ［３，４−ｃ］ナフチリジン類、これらの類似体、および方法 |
| EP1863814A1 (en) | 2005-04-01 | 2007-12-12 | Coley Pharmaceutical Group, Inc. | 1-substituted pyrazolo (3,4-c) ring compounds as modulators of cytokine biosynthesis for the treatment of viral infections and neoplastic diseases |
| WO2008144253A1 (en) * | 2007-05-14 | 2008-11-27 | Irm Llc | Protein kinase inhibitors and methods for using thereof |
| RS54560B1 (sr) | 2008-06-10 | 2016-06-30 | Abbvie Inc. | Triciklična jedinjenja |
| US20110212053A1 (en) * | 2008-06-19 | 2011-09-01 | Dapeng Qian | Phosphatidylinositol 3 kinase inhibitors |
| TW201024297A (en) * | 2008-09-10 | 2010-07-01 | Kalypsys Inc | Heterocyclic inhibitors of histamine receptors for the treatment of disease |
| JP2010143829A (ja) | 2008-12-16 | 2010-07-01 | Dainippon Sumitomo Pharma Co Ltd | 新規なイミダゾキノリン誘導体 |
| PE20120506A1 (es) * | 2009-03-19 | 2012-05-14 | Medical Res Council Technology | Derivados de pirazolopiridina como inhibidores de quinasas |
| CN102711476B (zh) | 2009-12-01 | 2014-12-03 | Abbvie公司 | 新的三环化合物 |
| RU2012127368A (ru) | 2009-12-01 | 2014-01-10 | Эбботт Лэборетриз | Новые трициклические соединения |
| TW201204727A (en) | 2010-03-10 | 2012-02-01 | Kalypsys Inc | Heterocyclic inhibitors of histamine receptors for the treatment of disease |
| KR101649610B1 (ko) | 2011-04-21 | 2016-08-19 | 오리제니스 게엠베하 | 키나아제 억제제로서의 헤테로사이클릭 화합물 |
| US10000482B2 (en) | 2012-10-19 | 2018-06-19 | Origenis Gmbh | Kinase inhibitors |
-
2012
- 2012-04-23 KR KR1020137030318A patent/KR101649610B1/ko active Active
- 2012-04-23 US US13/506,509 patent/US9499535B2/en active Active
- 2012-04-23 CA CA2831680A patent/CA2831680C/en active Active
- 2012-04-23 PH PH1/2013/502184A patent/PH12013502184A1/en unknown
- 2012-04-23 EP EP12716261.8A patent/EP2699572B1/en active Active
- 2012-04-23 SG SG2013077904A patent/SG194216A1/en unknown
- 2012-04-23 CN CN201280019590.1A patent/CN103717597B/zh active Active
- 2012-04-23 TW TW101114347A patent/TWI557121B/zh active
- 2012-04-23 BR BR112013026744-5A patent/BR112013026744B1/pt active IP Right Grant
- 2012-04-23 EA EA201301183A patent/EA034193B1/ru unknown
- 2012-04-23 AU AU2012244549A patent/AU2012244549B2/en active Active
- 2012-04-23 WO PCT/EP2012/001736 patent/WO2012143143A1/en not_active Ceased
- 2012-04-23 AP AP2013007252A patent/AP2013007252A0/xx unknown
- 2012-04-23 JP JP2014505543A patent/JP6278406B2/ja active Active
- 2012-04-23 PE PE2013002375A patent/PE20140927A1/es active IP Right Grant
- 2012-04-23 MX MX2013012295A patent/MX365784B/es active IP Right Grant
-
2013
- 2013-10-14 TN TNP2013000422A patent/TN2013000422A1/fr unknown
- 2013-10-20 IL IL228967A patent/IL228967B/en active IP Right Grant
- 2013-10-21 EC ECSP13012984 patent/ECSP13012984A/es unknown
- 2013-10-21 CU CU2013000144A patent/CU20130144A7/es unknown
- 2013-10-21 CL CL2013003052A patent/CL2013003052A1/es unknown
- 2013-10-21 CO CO13249434A patent/CO6831983A2/es not_active Application Discontinuation
- 2013-10-21 CR CR20130537A patent/CR20130537A/es unknown
- 2013-10-22 GT GT201300259A patent/GT201300259A/es unknown
- 2013-11-14 MA MA36429A patent/MA35123B1/fr unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103717597B (zh) | 作为激酶抑制剂的杂环化合物 | |
| CN103492389B (zh) | 用作激酶抑制剂的吡唑并[4,3-d]嘧啶 | |
| CA2777902C (en) | Compounds with p13 kinase inhibitor activity | |
| TW202106669A (zh) | 作為ｍｒｇｘ２抑制劑之３—胺基—４ｈ—苯并［ｅ］［１，２，４］噻二嗪１，１—二氧化物衍生物 | |
| TWI816704B (zh) | 苯并咪唑衍生物及其用途 | |
| JP6339564B2 (ja) | 抗マラリア剤としてのピリミジノン誘導体 | |
| CA3180058A1 (en) | Pyrazolo[1,5-a]pyrimidine derivatives having multimodal activity against pain | |
| HK1192247B (en) | Heterocyclic compounds as kinase inhibitors | |
| HK1192248B (en) | Pyrazolo[4,3-d]pyrimidines useful as kinase inhibitors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |